(0.32%) 5 116.18 points
(0.30%) 38 354 points
(0.36%) 15 986 points
(-1.01%) $83.00
(5.36%) $2.03
(0.29%) $2 354.00
(0.40%) $27.65
(4.14%) $960.25
(-0.27%) $0.932
(-0.46%) $10.97
(-0.57%) $0.796
(1.66%) $93.40
@ $0.562
発行日: 13 2月 2024 @ 01:22
リターン: -21.96%
前回のシグナル: 2月 8 - 01:41
前回のシグナル:
リターン: 4.13 %
Live Chart Being Loaded With Signals
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults...
Stats | |
---|---|
本日の出来高 | 279 879 |
平均出来高 | 603 533 |
時価総額 | 13.03M |
EPS | $-22.40 ( 2024-03-10 ) |
次の収益日 | ( $0 ) 2024-06-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0.110 |
ATR14 | $0.00300 (0.68%) |
ボリューム 相関
Redhill Biopharma Ltd 相関
10 最も負の相関 | |
---|---|
MGI | -0.956 |
CCRC | -0.944 |
PWOD | -0.942 |
STIM | -0.937 |
NWFL | -0.935 |
IMMR | -0.933 |
ROST | -0.93 |
HZNP | -0.929 |
ACAHU | -0.924 |
EWEB | -0.924 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Redhill Biopharma Ltd 相関 - 通貨/商品
Redhill Biopharma Ltd 財務諸表
Annual | 2023 |
収益: | $6.51M |
総利益: | $3.06M (47.03 %) |
EPS: | $3.68 |
FY | 2023 |
収益: | $6.51M |
総利益: | $3.06M (47.03 %) |
EPS: | $3.68 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
収益: | $61.80M |
総利益: | $28.46M (46.06 %) |
EPS: | $-38.27 |
Financial Reports:
No articles found.
Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。